Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

977.41 -26.16 (-2.61%)
Streaming Delayed Price Updated: 3:39 PM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company’s Directors and Officers for Breach of Fiduciary Duties – LLY
From Scott+Scott Attorneys at Law LLP
Via Business Wire
News headline image
Eli Lilly Just Delivered Fantastic News to Shareholders ↗
The stock price has climbed in the triple digits over three years. 
Via The Motley Fool
Topics Government
News headline image
Eli Lilly&#39;s 2026 Outlook Push Back Demand Fears: Analyst ↗
Cantor says Eli Lilly's 2026 outlook eases GLP-1 pricing worries, raises its price target, and expects strong sales growth driven by incretin drugs and orforglipron prescriptions. 
Via Benzinga
News headline image
Trump Administration To Launch TrumpRx Platform For Discounted Drugs Later On Thursday: Reports ↗
The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes... 
Via Stocktwits
Topics Economy Government World Trade
News headline image
P/E Ratio Insights for Eli Lilly and Co ↗
 
Via Benzinga
Eli Lilly & Co (NYSE:LLY) Stands Out in Recent CANSLIM Growth Stock Screen ↗
Via Chartmill
Thursday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs. ↗
Structure Therapeutics has a promising GLP-1 drug that is about to enter phase 3 trials. 
Via The Motley Fool
News headline image
Why Eli Lilly (LLY) Shares Are Getting Obliterated Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 7.4% in the morning session after the company discontinued three clinical pipeline assets, including a gene therapy for dementia... 
Via StockStory
Topics Artificial Intelligence
News headline image
Healthcare Titans Propel Dow to Record Highs as GLP-1 Sales Spark Major Market Rotation
As the first week of February 2026 unfolds, a dramatic shift in investor sentiment has split the U.S. stock market. While technology and artificial intelligence stocks have faced a sharp pullback, the... 
Via MarketMinute
Topics Artificial Intelligence Earnings Intellectual Property
Eli Lilly Stock Notches Best Day In 9 Months: Touts $50 Medicare For Obesity Drugs As ‘Compelling Value Proposition’ After Q4 Beat ↗
Via Stocktwits
News headline image
Why Eli Lilly Stock Just Dropped ↗
Hims & Hers has a GLP-1 weight loss pill -- and it's the cheapest one out there. 
Via The Motley Fool
News headline image
HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling? ↗
The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month. 
Via Stocktwits
Topics Intellectual Property
News headline image
Eli Lilly Beats Q4 Estimates But Shares Slide: Analyst Expects &#39;Clear Runway Into Next Decade&#39; ↗
Eli Lilly beats Q4 estimates, backed by sales of Zepbound and Mounjaro. Analyst maintains outperform rating, raises PT to $1,300. 
Via Benzinga
News headline image
Alphabet Inc. (GOOGL): The AI Powerhouse Reaches a $400 Billion Milestone Amid Antitrust Crossroads
As of February 5, 2026, Alphabet Inc. (NASDAQ: GOOGL) stands at a historic crossroads. The company recently capped off a blockbuster fiscal year 2025, becoming the first digital advertising giant to... 
Via Finterra
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Hims Is Already Knocking Off Novo's Wegovy Pill — For Just $49 A Month ↗
Hims & Hers Health launched a knockoff version of Novo Nordisk's already popular weight-loss pill on Thursday. 
Via Investor's Business Daily
News headline image
The $1 Trillion Apothecary: A Deep-Dive Research Report on Eli Lilly (LLY)
As of February 5, 2026, Eli Lilly and Company (NYSE: LLY) stands as a paradigm-shifting titan in the global healthcare landscape. Having recently crossed the historic $1 trillion market capitalization... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles ↗
Via MarketBeat
News headline image
Expert Outlook: Eli Lilly and Co Through The Eyes Of 15 Analysts ↗
 
Via Benzinga
News headline image
Eli Lilly Shares Boosted BY GLP-1s ↗
On Wednesday, Eli Lilly reported earnings well above expectations, and its shares initially rose by 10%. 
Via Talk Markets
News headline image
Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party? ↗
Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can. 
Via The Motley Fool
News headline image
LLY Q4 Deep Dive: Obesity Medicines, Pipeline Progress, and Market Expansion Drive Outperformance
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 42.6% year on year to $19.29 billion. The company’s full-year... 
Via StockStory
News headline image
Why Eli Lilly Stock Soared Today ↗
The healthcare giant gained nearly $100 billion in market value. 
Via The Motley Fool
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
In Weight Loss Drug Battle For 2026, Eli Lilly Pulls Ahead Of Novo Nordisk ↗
Novo Nordisk shares slide after weak 2026 guidance, while Eli Lilly rallies on strong earnings, booming weight loss drug sales, and a broader pipeline advantage. 
Via Benzinga
Wednesday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Nasdaq Dips Over 400 Points; Eli Lilly Shares Surge Following Upbeat Earnings ↗
 
Via Benzinga
News headline image
Eli Lilly Q4 2025 Earnings Call Transcript ↗
Eli Lilly and Company (NYSE:LLY) reported fourth-quarter financial results on Wednesday. The transcript from the earnings call has been provided below. 
Via Benzinga
Topics Earnings
News headline image
Eli Lilly (LLY) Stock Trades Up, Here Is Why
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 10% in the afternoon session after the company reported fourth-quarter 2025 results that beat Wall Street expectations and issued an... 
Via StockStory
News headline image
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 ↗
Eli Lilly is riding the GLP-1 gravy train, while this competitor is struggling to get on board. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.